MIAMI, Jan. 25 /PRNewswire/ -- When football season kicked off, Novartis Pharmaceuticals Corporation pledged a $1,000 donation to the Terrell Davis Migraine Foundation for each touchdown Terrell scored during the regular season. As a result of Davis' MVP season, Novartis will present him with a check in the amount of $25,000 to the Foundation. Terrell Davis has suffered from migraine headaches since the age of seven. His debilitating condition gained national attention when a sudden migraine hit him during Super Bowl XXXII. Davis was able to overcome his migraine and score the winning touchdown after being treated with DHE (dihydroergotamine mesylate) -- a product now available from Novartis as Migranal(R) Nasal Spray*. The Terrell Davis Migraine Foundation, headquartered in Englewood, Colorado, was established to help raise national awareness about the impact of living with headaches, particularly migraine, and serves to educate sufferers and their families about treatment options. The Foundation is funded by Terrell Davis, public donations and with the help of a start-up grant from Novartis Pharmaceuticals Corporation. Since its inception, the Terrell Davis Migraine Foundation efforts have included the production of a motivational video they will distribute to primary and secondary schools. In addition, local youth migraine sufferers have been hosted at select Bronco football games for an opportunity to meet Terrell and learn about his experience with migraine headaches and the importance of seeking medical care. "We are very excited to support the NFL MVP with his migraine Foundation," said Chris Tama, vice president, central nervous systems, Novartis Pharmaceuticals Corporation. "We share a common goal with Terrell and want to help the Foundation accomplish its goal of educating and providing support for the over 20 million Americans who suffer from migraine headaches." "I am grateful to Novartis for their contribution and support of the Foundation," said Davis. "I know first-hand the tremendous toll that migraine headaches take on a person's life. I've learned that there are effective treatments that enable me to 'get back in the game.' By providing the proper resources and education, the Foundation can help other sufferers improve their 'game' of life." For more information about the Terrell Davis Foundation for migraine education, consumers can call 800-426-8786. Novartis is a world leader in Life Sciences with core business in Healthcare, Agribusiness and Nutrition. In 1997, Novartis Group sales were 31.2 billion Swiss francs (USD 21.6 billion), of which 18.8 billion (USD 13.0 billion) were in Healthcare, 8.3 billion (USD 5.8 billion) in Agribusiness and 4.1 billion (USD 2.8 billion) in Nutrition. The group annually invests more than 3.6 billion Swiss francs (USD 2.5 billion) in R&D. Headquartered in Basel, Switzerland, Novartis employs about 86,000 people and operates in over 100 countries around the world. * Migranal Nasal Spray, indicated for the acute treatment of migraine headaches, was made available by prescription in pharmacies nationwide in January 1998. In clinical trials, self-administration of Migranal Nasal Spray resulted in migraine pain relief and reduction in pain intensity. Over 50 percent of patients in pivotal clinical trials did not need additional medications during the 24-hour period following a single 2 mg Migranal treatment. In clinical trials, side effects were usually mild and transient. The most common were rhinitis, altered sense of taste, nausea, vomiting, dizziness and application site reaction. Full prescribing information is available from Novartis Pharmaceuticals Corporation.
SOURCE Novartis Pharmaceuticals Corporation